In:
Cytometry Part B: Clinical Cytometry, Wiley, Vol. 104, No. 4 ( 2023-07), p. 294-303
Abstract:
Multiparametric flow cytometry (MFC) has become a powerful tool in minimal residual disease (MRD) detection in B‐lymphoblastic leukemia/lymphoma (B‐ALL). In the setting of targeted immunotherapy, B‐ALL MRD detection often relies on alterative gating strategies, such as the utilization of CD22 and CD24. It is important to depict the full diversity of normal cell populations included in the alternative B‐cell gating methods to avoid false‐positive results. We describe two CD22‐positive non‐neoplastic cell populations in the peripheral blood (PB), including one progenitor population of uncertain lineage and one mature B‐cell population, which are immunophenotypic mimics of B‐ALL. Methods Using MFC, we investigated the prevalence and phenotypic profiles of both CD22‐positive populations in 278 blood samples from 52 patients with B‐ALL; these were obtained pre‐ and post‐treatment with CD19 and/or CD22 CAR‐T therapies. We further assessed whether these two populations in the blood were exclusively associated with B‐ALL or recent anticancer therapies, by performing the same analysis on patients diagnosed with other hematological malignancies but in long‐term MRD remission. Results The progenitor population and mature B‐cell population were detected at low levels in PB of 61.5% and 44.2% of B‐ALL patients, respectively. Both cell types showed distinctive and highly consistent antigen expression patterns that are reliably distinguishable from B‐ALL. Furthermore, their presence is not restricted solely to B‐ALL or recent therapy. Conclusions Our findings aid in building a complete immunophenotypic profile of normal cell populations in PB, thereby preventing misdiagnosis of B‐ALL MRD and inappropriate management.
Type of Medium:
Online Resource
ISSN:
1552-4949
,
1552-4957
DOI:
10.1002/cyto.b.v104.4
DOI:
10.1002/cyto.b.22104
Language:
English
Publisher:
Wiley
Publication Date:
2023
detail.hit.zdb_id:
2180651-2
SSG:
12
Permalink
